Loxo Oncology Inc. (NASDAQ:LOXO)’s share price was up 7.7% during trading on Wednesday . The company traded as high as $28.24 and last traded at $27.01, with a volume of 230,897 shares trading hands. The stock had previously closed at $25.07.

LOXO has been the topic of several analyst reports. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Stifel Nicolaus decreased their price target on shares of Loxo Oncology from $37.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, March 16th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Loxo Oncology in a report on Tuesday, April 19th. Finally, Citigroup Inc. lifted their price target on shares of Loxo Oncology from $24.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, March 16th. Five equities research analysts have rated the stock with a buy rating, Loxo Oncology has an average rating of “Buy” and a consensus price target of $29.60.

The firm’s market capitalization is $526.01 million. The company has a 50 day moving average of $24.90 and a 200-day moving average of $23.20.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.10. On average, analysts predict that Loxo Oncology Inc. will post ($2.28) EPS for the current fiscal year.

In other news, major shareholder Aisling Capital Iii Lp purchased 232,558 shares of Loxo Oncology stock in a transaction dated Tuesday, May 17th. The shares were bought at an average cost of $21.50 per share, for a total transaction of $4,999,997.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

A number of institutional investors have modified their holdings of the stock. Casdin Capital LLC purchased a new position in shares of Loxo Oncology during the fourth quarter worth $7,155,000. AWM Investment Company Inc. raised its position in shares of Loxo Oncology by 40.0% in the fourth quarter. AWM Investment Company Inc. now owns 105,000 shares of the biopharmaceutical company’s stock worth $2,987,000 after buying an additional 30,000 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Loxo Oncology during the fourth quarter worth $1,055,000. Finally, Aisling Capital LLC raised its position in shares of Loxo Oncology by 10.0% in the fourth quarter. Aisling Capital LLC now owns 3,796,362 shares of the biopharmaceutical company’s stock worth $108,006,000 after buying an additional 343,869 shares during the last quarter.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.